Sphere Bio
Generated by Meeveem AI
"Pioneering picodroplet microfluidics for single cell analysis and isolation in biologics discovery"
Royston
•51 - 250 Employees
•Medical Devices
About Sphere Bio
Sphere Bio delivers picodroplet microfluidic platforms that enable scientists to screen, analyse and isolate single cells at unprecedented scale. Its Cyto-Mine technology can process up to 40 million cells in a day, combining high-throughput multiplexing with verified monoclonality and viable single cell dispensing. The platforms serve researchers in antibody discovery, cell line development and cell therapy. The company's approach encapsulates individual cells in tiny droplets, creating biocompatible environments where cells can be measured and selected with precision. This technology accelerates research timelines and helps scientists find rare, high-value cells that drive breakthroughs in therapeutics and biologics development.
80
Team Members
2010
Founded
Medical Devices
Sector
Hybrid
Work Environment
Our Vision
A world where every valuable cell is discovered, where researchers can screen millions of candidates in hours rather than weeks, unlocking breakthroughs in antibodies, therapeutics and cell engineering that transform human health.
Our Mission
Sphere Bio develops picodroplet microfluidic platforms that enable scientists to find, analyse and isolate the most valuable cells with speed, precision and verified monoclonality.